Covid-19 Impact on NGS Services Market, Global Research Reports 2020-2021

2 Global NGS Services Quarterly Market Size Analysis

• 2.1 NGS Services Business Impact Assessment - COVID-19
  • 2.1.1 Global NGS Services Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global NGS Services Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global NGS Services Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, NGS Services Headquarters and Area Served
• 3.3 Date of Key Players Enter into NGS Services Market
• 3.4 Key Players NGS Services Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on NGS Services Segments, By Type

• 4.1 Introduction
  • 1.4.1 RNA-Seq
  • 1.4.2 Exome
• 4.2 By Type, Global NGS Services Market Size, 2019-2021

5 Impact of Covid-19 on NGS Services Segments, By Application

• 5.1 Overview
  • 5.5.1 Oncology
  • 5.5.2 Lung cancer
  • 5.5.3 Breast cancer
  • 5.5.4 Prostate cancer
  • 5.5.5 Colorectal cancer
  • 5.5.6 Others
• 5.2 By Application, Global NGS Services Market Size, 2019-2021
  • 5.2.1 By Application, Global NGS Services Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Beijing Genomics Institute (BGI)
  • 7.1.1 Beijing Genomics Institute (BGI) Business Overview
  • 7.1.2 Beijing Genomics Institute (BGI) NGS Services Quarterly Revenue, 2020
  • 7.1.3 Beijing Genomics Institute (BGI) NGS Services Product Introduction
  • 7.1.4 Beijing Genomics Institute (BGI) Response to COVID-19 and Related Developments
• 7.2 Cegat (Centre for Genomics and Transcriptomics) GMBH
  • 7.2.1 Cegat (Centre for Genomics and Transcriptomics) GMBH Business Overview
  • 7.2.2 Cegat (Centre for Genomics and Transcriptomics) GMBH NGS Services Quarterly Revenue, 2020
  • 7.2.3 Cegat (Centre for Genomics and Transcriptomics) GMBH NGS Services Product Introduction
  • 7.2.4 Cegat (Centre for Genomics and Transcriptomics) GMBH Response to COVID-19 and Related Developments
• 7.3 DNA Vision SA
  • 7.3.1 DNA Vision SA Business Overview
  • 7.3.2 DNA Vision SA NGS Services Quarterly Revenue, 2020
  • 7.3.3 DNA Vision SA NGS Services Product Introduction
  • 7.3.4 DNA Vision SA Response to COVID-19 and Related Developments
• 7.4 Eurofins Genomics Inc.
  • 7.4.1 Eurofins Genomics Inc. Business Overview
  • 7.4.2 Eurofins Genomics Inc. NGS Services Quarterly Revenue, 2020
  • 7.4.3 Eurofins Genomics Inc. NGS Services Product Introduction
  • 7.4.4 Eurofins Genomics Inc. Response to COVID-19 and Related Developments
• 7.5 Febit / Comprehensive Biomarker Center GMBH (CBC)
  • 7.5.1 Febit / Comprehensive Biomarker Center GMBH (CBC) Business Overview
  • 7.5.2 Febit / Comprehensive Biomarker Center GMBH (CBC) NGS Services Quarterly Revenue, 2020
  • 7.5.3 Febit / Comprehensive Biomarker Center GMBH (CBC) NGS Services Product Introduction
  • 7.5.4 Febit / Comprehensive Biomarker Center GMBH (CBC) Response to COVID-19 and Related Developments
• 7.6 Genomnia SRL
  • 7.6.1 Genomnia SRL Business Overview
  • 7.6.2 Genomnia SRL NGS Services Quarterly Revenue, 2020
  • 7.6.3 Genomnia SRL NGS Services Product Introduction
  • 7.6.4 Genomnia SRL Response to COVID-19 and Related Developments
• 7.7 Mina Inc.
  • 7.7.1 Mina Inc. Business Overview
  • 7.7.2 Mina Inc. NGS Services Quarterly Revenue, 2020
  • 7.7.3 Mina Inc. NGS Services Product Introduction
  • 7.7.4 Mina Inc. Response to COVID-19 and Related Developments
• 7.8 Macrogen Inc.
  • 7.8.1 Macrogen Inc. Business Overview
  • 7.8.2 Macrogen Inc. NGS Services Quarterly Revenue, 2020
  • 7.8.3 Macrogen Inc. NGS Services Product Introduction
  • 7.8.4 Macrogen Inc. Response to COVID-19 and Related Developments
• 7.9 Microsynth AG
  • 7.9.1 Microsynth AG Business Overview
  • 7.9.2 Microsynth AG NGS Services Quarterly Revenue, 2020
  • 7.9.3 Microsynth AG NGS Services Product Introduction
  • 7.9.4 Microsynth AG Response to COVID-19 and Related Developments
• 7.10 Seqomics
  • 7.10.1 Seqomics Business Overview
  • 7.10.2 Seqomics NGS Services Quarterly Revenue, 2020
  • 7.10.3 Seqomics NGS Services Product Introduction
  • 7.10.4 Seqomics Response to COVID-19 and Related Developments
• 7.11 Source Bio Science
  • 7.11.1 Source Bio Science Business Overview
  • 7.11.2 Source Bio Science NGS Services Quarterly Revenue, 2020
  • 7.11.3 Source Bio Science NGS Services Product Introduction
  • 7.11.4 Source Bio Science Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US